Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults (Q37883008)

24 August 2017

1 reference

title

Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults (English)

1 reference

24 August 2017

1 reference

1 reference

lymphoblastic leukemia

1 reference

2

Stephen P Hunger

1 reference

24 August 2017

Eric S Schafer

1

1 reference

PubMed ID

21629213

24 August 2017

language of work or name

English

0 references

publication date

31 May 2011

1 reference

Nature Reviews Clinical Oncology

24 August 2017

1 reference

24 August 2017

8

1 reference

24 August 2017

417-424

1 reference

24 August 2017

7

1 reference

Trends in 5- and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990-2004.

24 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Registration and classification of adolescent and young adult cancer cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Site of oncologic specialty care for older adolescents in Utah.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Access to pediatric cancer care by age, race, and diagnosis, and outcomes of cancer treatment in pediatric and adolescent patients in the state of Georgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Patterns of care and survival for children with acute lymphoblastic leukaemia diagnosed between 1980 and 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Recruitment of adolescents and young adults to cancer clinical trials--international comparisons, barriers, and implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Acute lymphoblastic leukemia in adolescents and young adults in Finland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Improved prognosis for older adolescents with acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Role of allogeneic hematopoietic cell transplantation in adults with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Origins of chromosome translocations in childhood leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Clinical relevance of in vitro drug resistance testing in childhood acute lymphoblastic leukemia: the state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

The optimal use of steroids in paediatric acute lymphoblastic leukaemia: no easy answers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Developmental pharmacology--drug disposition, action, and therapy in infants and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Adolescents' compliance with therapeutic regimens. Psychological and social aspects and intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Non-compliance with oral chemotherapy in childhood leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

21 January 2018

Adherence to Medication

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Understanding medication adherence in pediatric acute lymphoblastic leukemia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Underinsurance among children in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Quality cancer care for adolescents and young adults: a position statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Update on developmental therapeutics for acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

TEL-AML1 fusion in acute lymphoblastic leukaemia of adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Use of paediatric versus adult oncology treatment centres by adolescents 15-19 years old: the Canadian Childhood Cancer Surveillance and Control Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Survival in childhood acute lymphocytic leukemia: effect of protocol and place of treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Young adults 16-21 years of age at diagnosis entered on Childrens Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Results of treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Aging out of coverage: young adults with special health needs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Delays in cancer diagnosis in underinsured young adults and older adolescents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Starting an adolescent and young adult program: some success stories and some obstacles to overcome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.77

Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia

31 March 2020

1 reference

12 December 2020

Young adults and the Affordable Care Act of 2010.

1 reference

12 December 2020

Access to specialized pediatric cancer care in Switzerland.

1 reference

12 December 2020

Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance

1 reference

12 December 2020

The effect of age, gender, and sexual maturation on the caffeine breath test

1 reference

12 December 2020

Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Mün

1 reference

12 December 2020

Patterns of care among adolescents with malignancy in Ohio

1 reference

12 December 2020

10.1038/NRCLINONC.2011.77

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21629213